866-997-4948(US-Canada Toll Free)

Influenza A Virus, H1N1 Subtype Infections Global Clinical Trials Review, H2, 2017

Published By :

GlobalData

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 144 Pages

Influenza A Virus, H1N1 Subtype Infections Global Clinical Trials Review, H2, 2017

Summary

GlobalDatas clinical trial report, Influenza A Virus, H1N1 Subtype Infections Global Clinical Trials Review, H2, 2017" provides an overview of Influenza A Virus, H1N1 Subtype Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Influenza A Virus, H1N1 Subtype Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Influenza A Virus, H1N1 Subtype Infections to Infectious Disease Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Influenza A Virus, H1N1 Subtype Infections to Infectious Disease Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Influenza A Virus, H1N1 Subtype Infections 33
Aug 23, 2017: Novavax Preclinical Influenza Nanoparticle Study Published in Vaccine 33
Clinical Trial Profile Snapshots 34
Appendix 142
Abbreviations 142
Definitions 142
Research Methodology 143
Secondary Research 143
About GlobalData 144
Contact Us 144
Source 144

List of Tables
Influenza A Virus, H1N1 Subtype Infections Therapeutics, Global, Clinical Trials by Region, 2017* 7
Influenza A Virus, H1N1 Subtype Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Influenza A Virus, H1N1 Subtype Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 14
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
Proportion of Influenza A Virus, H1N1 Subtype Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 16
Influenza A Virus, H1N1 Subtype Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Influenza A Virus, H1N1 Subtype Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Influenza A Virus, H1N1 Subtype Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 19
Influenza A Virus, H1N1 Subtype Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Influenza A Virus, H1N1 Subtype Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
Influenza A Virus, H1N1 Subtype Infections Therapeutics, Global, Clinical Trials by Phase, 2017* 22
Influenza A Virus, H1N1 Subtype Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
Influenza A Virus, H1N1 Subtype Infections Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
Influenza A Virus, H1N1 Subtype Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32

List of Figures
Influenza A Virus, H1N1 Subtype Infections Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Influenza A Virus, H1N1 Subtype Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Influenza A Virus, H1N1 Subtype Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 14
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
Proportion of Influenza A Virus, H1N1 Subtype Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 16
Influenza A Virus, H1N1 Subtype Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Influenza A Virus, H1N1 Subtype Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Influenza A Virus, H1N1 Subtype Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 19
Influenza A Virus, H1N1 Subtype Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Influenza A Virus, H1N1 Subtype Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
Influenza A Virus, H1N1 Subtype Infections Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
Influenza A Virus, H1N1 Subtype Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
Influenza A Virus, H1N1 Subtype Infections Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
Influenza A Virus, H1N1 Subtype Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
Influenza A Virus, H1N1 Subtype Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32
GlobalData Methodology 143

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *